UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

The New England journal of medicine, 2013-03, Vol.368 (13), p.1210-1219

2013

Volltextzugriff (PDF)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults

Headache, 2019-11, Vol.59 (10), p.1731-1742

2019

Volltextzugriff (PDF)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

Cephalalgia, 2019-10, Vol.39 (11), p.1455-1464

2019

Volltextzugriff (PDF)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Headache, 2021-06, Vol.61 (6), p.927-935

2021

Volltextzugriff (PDF)

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

Journal of headache and pain, 2021-09, Vol.22 (1), p.110-110, Article 110

2021

Volltextzugriff (PDF)

Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study

The journal of clinical endocrinology and metabolism, 2009-12, Vol.94 (12), p.4860-4867

2009

Volltextzugriff (PDF)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

Journal of headache and pain, 2018-10, Vol.19 (1), p.92-92, Article 92

2018

Volltextzugriff (PDF)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Journal of headache and pain, 2021-07, Vol.22 (1), p.81-81, Article 81

2021

Volltextzugriff (PDF)

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity

The journal of clinical endocrinology and metabolism, 2011-01, Vol.96 (1), p.E9-E18

2011

Volltextzugriff (PDF)

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

BMJ open, 2023-08, Vol.13 (8), p.e068616-e068616

2023

Volltextzugriff (PDF)

Gelatinase A (MMP-2) Is Necessary and Sufficient for Renal Tubular Cell Epithelial-Mesenchymal Transformation

The American journal of pathology, 2003-06, Vol.162 (6), p.1937-1949

2003

Volltextzugriff (PDF)

YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis

Biochemical and biophysical research communications, 2010-07, Vol.398 (3), p.482-488

2010

Volltextzugriff (PDF)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

European journal of neurology, 2021-05, Vol.28 (5), p.1716-1725

2021

Volltextzugriff (PDF)

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Cephalalgia, 2018-09, Vol.38 (10), p.1611-1621

2018

Volltextzugriff (PDF)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial

Neurology, 2019-05, Vol.92 (20), p.e2309

2019

Volltextzugriff (PDF)

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Neurology, 2017-09, Vol.89 (12), p.1237-1243

2017

Volltextzugriff (PDF)

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Cephalalgia, 2020-05, Vol.40 (6), p.543-553

2020

Volltextzugriff (PDF)

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-01, Vol.317 (2), p.156

2017

Volltextzugriff (PDF)

Vascular safety of erenumab for migraine prevention

Neurology, 2020-02, Vol.94 (5), p.e497

2020

Volltextzugriff (PDF)

Associations Between Hemoglobin Level, Resource Use, and Medical Costs in Patients With Heart Failure: Findings From HF-ACTION

Journal of cardiac failure, 2012-10, Vol.18 (10), p.784-791

2012

Volltextzugriff (PDF)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine

Headache, 2021-04, Vol.61 (4), p.653-661

2021

Volltextzugriff (PDF)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

Nephrology, dialysis, transplantation, 2020-10, Vol.35 (10), p.1769-1778

2020

Volltextzugriff (PDF)

FC 078REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS: A FACILITY CALCIMIMETIC PREFERENCE APPROACH

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Efficacy of Erenumab in Chronic Migraine Patients With and Without Allodynia (P2.10-025)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

US Hemodialysis Facilities Switching from Cinacalcet to Etelcalcetide: Impact on Parathyroid Hormone (PTH) Levels: PO0546

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.208-209

2021

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

Gelatinase A (MMP-2) Is Necessary and Sufficient for Renal Tubular Cell Epithelial-Mesenchymal Transformation

YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial

Vascular safety of erenumab for migraine prevention

Associations Between Hemoglobin Level, Resource Use, and Medical Costs in Patients With Heart Failure: Findings From HF-ACTION

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

FC 078REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS: A FACILITY CALCIMIMETIC PREFERENCE APPROACH

Efficacy of Erenumab in Chronic Migraine Patients With and Without Allodynia (P2.10-025)

US Hemodialysis Facilities Switching from Cinacalcet to Etelcalcetide: Impact on Parathyroid Hormone (PTH) Levels: PO0546

Suchergebnisse filtern